News

AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...
AstraZeneca and Daiichi Sankyo’s Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...
Pharmaceutical Technology on MSN6d
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.
Fierce Pharma6d
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
CURE6d
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...
Fierce Pharma3d
Fierce Pharma Asia—Vor-RemeGen, Otsuka-Harbour autoimmune deals; Datroway's lung cancer nod
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
The Pharma Letter6d
Datroway first US-approved TROP2-directed therapy in lung cancer
The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with ...
Zacks Investment Research on MSN6d
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small ...
Medical Dialogues4d
AstraZeneca Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have ...
pharmaphorum6d
AZ, Daiichi get Datroway nod in lung cancer on second try
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
MPR4d
Datroway Gains Approval for Previously-Treated EGFR-Mutated NSCLC
The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...